🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Sotera Health Company SHC R3KPHARMA

Healthcare · Diagnostics & Research · United States
https://soterahealth.com
Company Profile ↓
$18.59
+18.26% 1Y
Mkt Cap$5.31B
P/E32.61
P/B8.03
52W High$19.57
52W Low$13.13
Book Value$2.33
EPS (TTM)$0.57

Company Overview

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 27.8%, reflecting efficient use of shareholder capital.

Healthy Margins

Operating margin of 38.0% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.16B (+5.7% YoY); net profit $77.95M.
  • Trailing 12 Months Year-on-year growth — revenue +9.2%, earnings +569.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.38%
1 Year:9.20%

Compounded Profit Growth

5 Years:-
1 Year:569.50%

Stock Price Performance

1 Year:+18.26%
6 Months:+27.59%
3 Months:+17.21%
1 Month:-1.43%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 85% of range
$13.13 $19.57
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)47.19 · Neutral
Price Performance
1M-1.43%
3M+17.21%
6M+27.59%
1Y+18.26%
Valuation vs Sector

P/E of 32.61 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 27.8%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
32.61
Industry PE
24.83
Forward P/E
17.30
PEG Ratio
1.31
Book Value
$2.33
Price to Book
8.03
P/S
4.39
EV/EBITDA
12.59
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
8.38%
Profit 5Y
-
Revenue (YoY)
9.20%
Earnings (YoY)
569.50%

Profitability & Returns

ROCE
12.01%
ROE
27.78%
ROA
8.60%
Profit Margin
13.44%
Op Margin
37.96%
Gross Margin
54.97%
EPS (Latest Qtr)
$0.19
EPS (TTM)
$0.57

Balance Sheet & Liquidity

Debt/Equity
3.41
Quick Ratio
2.40
Current Ratio
2.80
Debt
$2.27B
Total Assets
$3.31B
Current Assets
$585.97M
Working Capital
$363.83M

Ownership

Promoter Holding
2.40%
Chg in Prom Hold
0.20%
FII / Inst Holding
105.70%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
$5.31B
Total Revenue (TTM)
$1.22B
EBITDA
$576.58M
Free Cash Flow
$153.97M
Operating Cash Flow
$292.19M
Shares Outstanding
285.37M
Gross Margin
54.97%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SHC Sotera Health Company R3KPHARMA 18.59 32.61 $5.31B 0.00% 12.01% 27.78% 8.38% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 188.20M213.09M200.03M212.15M251.92M226.16M236.75M266.64M248.70M220.59M255.28M263.18M248.18M276.59M285.47M-254.52M294.34M311.31M303.44M280.05M321.38M
Cost of Revenue ----------------119.09M127.72M133.75M137.52M132.98M-
Gross Profit 96.52M118.97M107.51M115.37M143.76M125.59M128.88M150.40M136.01M111.50M139.59M145.98M127.11M152.79M158.02M-135.43M166.62M177.56M165.92M147.07M177.96M
Operating Expenses ----------------78.39M78.19M66.38M60.54M71.24M-
Operating Income 44.87M61.74M47.03M46.36M78.27M65.67M53.49M71.50M63.20M33.37M63.20M76.10M53.17M76.80M80.51M-57.04M88.43M111.18M105.38M75.83M-
EBITDA ----------------66.86M94.56M140.44M138.07M108.17M-
Interest Expense ----------------40.88M40.65M39.15M35.05M34.74M-
Pretax Income -----------------14.82M18.90M72.94M70.50M42.61M-
Tax Provision -----------------1.56M10.94M24.54M35.65M16.02M-
Net Income -1.96M7.02M10.00K10.84M42.60M27.44M30.64M30.42M25.09M-23.51M-13.66M-8.75M17.00M--13.26M7.96M48.40M34.85M26.59M53.64M
Diluted EPS -0.010.030.000.040.150.100.110.110.090.010.08-0.050.020.030.06--0.050.030.170.120.090.19

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 778.33M818.16M-1.00B1.05B1.10B1.16B
Cost of Revenue ---446.68M472.13M498.15M518.08M
Gross Profit 395.43M443.57M-557.00M577.16M602.29M645.53M
Operating Expenses ---308.65M300.47M304.67M283.50M
Operating Income 183.60M206.02M-248.35M276.69M297.63M362.03M
EBITDA ----17.41M406.83M442.20M439.93M
Interest Expense ---80.14M142.88M164.69M155.72M
Pretax Income ----243.11M106.03M113.87M147.51M
Tax Provision ----9.54M54.65M69.48M69.56M
Net Income -20.85M-38.62M--233.57M51.38M44.40M77.95M
Diluted EPS -0.09-0.16--0.830.180.160.27

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --2.76B-3.12B3.13B3.07B3.26B
Current Assets ----645.01M557.24M526.04M613.41M
Cash & Equivalents --102.45M-395.21M296.41M277.24M344.62M
Inventory ----37.15M48.32M49.16M54.38M
Receivables ----118.48M147.70M140.33M139.33M
Total Liabilities --2.31B-2.77B2.69B2.67B2.66B
Current Liabilities --140.60M-791.57M230.65M191.00M249.58M
Long Term Debt --1.82B-1.75B2.22B2.21B2.13B
Total Debt ----2.03B2.33B2.35B2.27B
Total Equity 45.49M-641.13M452.30M-350.24M443.73M404.91M606.03M
Shares Outstanding ----286.04M286.04M286.04M286.04M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 149.04M120.58M-277.96M-147.73M224.16M287.19M
Investing Cash Flow -57.26M-158.69M--181.90M-214.91M-179.00M-135.14M
Financing Cash Flow -126.03M73.43M-197.76M265.96M-50.56M-100.53M
Capital Expenditure -57.26M-53.51M--182.38M-214.97M-179.07M-138.02M
Free Cash Flow 91.78M67.08M-95.58M-362.71M45.09M149.18M
Net Change in Cash ---293.83M-96.68M-5.40M51.52M
Share Buybacks 034.00M00---
Dividends Paid 691.17M00----

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 50.8%54.2%-55.5%55.0%54.7%55.5%
Operating Margin % 23.6%25.2%-24.7%26.4%27.0%31.1%
Net Margin % -2.7%-4.7%--23.3%4.9%4.0%6.7%
ROE % 3.3%-8.5%--66.7%11.6%11.0%12.9%
ROCE % -7.9%-10.7%9.5%10.3%12.0%

Shareholding Pattern

Insiders
2.40%
Institutions
105.70%
Public Float
108.31%

Top Institutional Holders

#Holder% HeldSharesValue
1 Sessa Capital IM, L.P. 9.48% 27.05M $506.65M
2 Darsana Capital Partners, LP 9.46% 27.00M $505.71M
3 Blackrock Inc. 8.46% 24.15M $452.30M
4 Sculptor Capital LP 8.41% 24.00M $449.52M
5 Sachem Head Capital Management, LP 5.45% 15.56M $291.44M
6 Vanguard Capital Management LLC 4.26% 12.17M $227.96M
7 Vanguard Portfolio Management LLC 4.19% 11.95M $223.75M
8 AQR Capital Management, LLC 3.76% 10.73M $201.05M
9 T. Rowe Price Investment Management, Inc. 3.69% 10.52M $197.01M
10 Jupiter Topco LLC 2.94% 8.40M $157.37M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SHC

Yahoo Finance Wed, 19 Aug 2026

Research Tools & Consumables Stocks Q2 Recap: Benchmarking Sotera Health Company (NASDAQ:SHC)

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Sotera Health Company (NASDAQ:SHC) and its peers.…

Yahoo Finance Sun, 16 Aug 2026

Sotera Health Company (SHC): Buy, Sell, or Hold Post Q2 Earnings?

Sotera Health Company trades at $19.02 per share and has stayed right on track with the overall market, gaining 11.3% over the last six months. At the same time, the S&P 500 has returned 13.1%.

Yahoo Finance hu, 13 Aug 2026

Sotera Health (SHC) Q2 2026 Earnings Call Transcript

Revenue hit $321 million with adjusted EPS up 30% year over year.

Yahoo Finance Mon, 10 Aug 2026

Sotera Health Company (SHC) Reported Positive Results Amid Litigation Wins

US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index’s 23% return. A copy of the letter can be downloaded here. The second quarter r…

Yahoo Finance Fri, 07 Aug 2026

Sotera Health Q2 Earnings Call Highlights

Sotera Health (NASDAQ:SHC) reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook. The company also marked …

Yahoo Finance hu, 06 Aug 2026

Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates

Sotera Health (SHC) delivered earnings and revenue surprises of +8.33% and +3.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SHC — Frequently Asked Questions

What is the current share price of Sotera Health Company (SHC)?

As of 2026-09-19 21:16 PDT, Sotera Health Company (SHC) trades at $18.59 on NasdaqGS. Its 52-week range is $13.13 to $19.57.

What is the market capitalisation of SHC?

Sotera Health Company (SHC) has a market capitalisation of $5.31B on NasdaqGS.

What is the P/E ratio of SHC?

SHC trades at a trailing price-to-earnings (P/E) ratio of 32.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.03.

What is the return on equity (ROE) of SHC?

SHC has a return on equity (ROE) of 27.78%. Its return on capital employed (ROCE) is 12.01%.

Is SHC a good stock to buy?

This page provides a data-driven analysis of Sotera Health Company (SHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space